Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $9.8252W HIGH $21.45
Volume
2.96 M
Value Traded
18.11 M
Short % Float
11.27%
-4.82%Week
-9.02%1 Month
-12.76%3 Month
+34.4%6 Month
-90.28%5 Year
-10.91%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.66 B
EPS (TTM)
-1.28
P/E Ratio
-
Ent. Value
1.22 B
Total Shares
116.45 M
Float Shares
104.67 M
Insiders
10.11%
Institutions
90.41%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
NVCR Catalyst Timeline
Dated clinical, regulatory and corporate events for NovoCure Limited
Catalyst Timeline
Dated clinical, regulatory & corporate events for NovoCure Limited
122Total events
5Upcoming
42Tier-1 (high impact)
2016 to 2026Coverage
Upcoming catalysts 2
Event history 50
▲FDA ApprovalFDA Decision
Japan MHLW approves Optune Pax for unresectable locally advanced pancreatic cancer
unresectable locally advanced pancreatic cancersource ↗
●R&D DayPresentation
Novocure management fireside chat at Morgan Stanley 24th Annual Global Healthcare Conference
●R&D DayPresentation
Novocure management fireside chat at Wells Fargo 21st Annual Healthcare Conference
▲Quarterly UpdateCorporate
Novocure reports Q2 2026 financial results with record net revenues of $183.6M
▲EU ApprovalEx-US Regulatory
CE Mark for Optune Pax in locally advanced pancreatic cancer
locally advanced pancreatic cancersource ↗
◆Topline ReadoutClinical Data
Topline data from Phase 3 TRIDENT trial
newly diagnosed glioblastomasource ↗
▲EU ApprovalEx-US Regulatory
Optune Pax received CE Mark for locally advanced pancreatic cancer
locally advanced pancreatic cancersource ↗
▲Product LaunchPost-Market
Germany first market to launch Optune Pax in EU
locally advanced pancreatic cancersource ↗
◆Topline ReadoutClinical Data
Topline data from Phase 3 TRIDENT trial in newly diagnosed GBM
newly diagnosed glioblastomasource ↗
▲Topline ReadoutClinical Data
Positive topline results from Phase 2 PANOVA-4 trial of TTFields therapy for metastatic pancreatic cancer
metastatic pancreatic cancersource ↗
◆Oral PresentationPresentation
Novocure management to participate in fireside chat at Leerink Global Healthcare Conference
▲Other Regulator MilestoneEx-US Regulatory
Optune Lua receives reimbursement approval in Japan for NSCLC
non-small cell lung cancersource ↗
▲Reimbursement / PricingPost-Market
Japan MHLW approval of reimbursement for Optune Lua
unresectable advanced/recurrent NSCLCsource ↗
▲Primary Endpoint MetClinical Data
PANOVA-4 topline results: primary endpoint met (74% DCR vs 48% historical control)
metastatic pancreatic cancersource ↗
▲FDA ApprovalFDA Decision
U.S. FDA approval of Optune Pax for pancreatic cancer
pancreatic cancersource ↗
●Quarterly UpdateCorporate
Conference call and webcast to discuss Q4 and full year 2025 financial results
▲Other Regulator MilestoneEx-US Regulatory
BC Cancer coverage for TTFields therapy in newly diagnosed glioblastoma
newly diagnosed glioblastomasource ↗
▲FDA ApprovalFDA Decision
FDA approval of Optune Pax for locally advanced pancreatic cancer
locally advanced pancreatic cancersource ↗
▲Primary Endpoint MetClinical Data
PANOVA-3 met primary endpoint of overall survival
locally advanced pancreatic cancersource ↗
●Full ResultsClinical Data
PANOVA-3 results published in Journal of Clinical Oncology
locally advanced pancreatic cancersource ↗
▲Other Regulator MilestoneEx-US Regulatory
BC Cancer coverage for Optune Gio in newly diagnosed GBM
newly diagnosed glioblastomasource ↗
◆Oral PresentationPresentation
Novocure management presentation at 44th Annual J.P. Morgan Healthcare Conference
▲Other Regulator MilestoneEx-US Regulatory
Czechia public health insurers coverage for Optune Gio in newly diagnosed GBM
newly diagnosed glioblastomasource ↗
▲Runway Guidance UpdateCorporate
Updated full year 2026 financial guidance: total net revenue $710M-$725M, adjusted EBITDA $0-$15M
◆Oral PresentationPresentation
Novocure management to participate in Piper Sandler Healthcare Conference fireside chat
◆Topline ReadoutClinical Data
Final data from phase 3 pivotal INNOVATE-3 trial
recurrent ovarian cancersource ↗
▲Topline ReadoutClinical Data
Positive results from Phase 3 LUNAR trial of Tumor Treating Fields therapy in non-small cell lung cancer
non-small cell lung cancersource ↗
▼Oral PresentationPresentation
Presentation at 2023 ASCO Annual Meeting revealing additional LUNAR study data
non-small cell lung cancersource ↗
▼Oral PresentationPresentation
Presentation at 2023 ASCO Annual Meeting revealing negative data
non-small cell lung cancersource ↗
◆Topline ReadoutClinical Data
Topline results from LUNAR study announced
non-small cell lung cancersource ↗
▲Primary Endpoint MetEF-31Clinical Data
EF-31 phase 2 pilot study meets primary endpoint of objective response rate
gastric adenocarcinomasource ↗
◆Topline ReadoutClinical Data
Final data from phase 3 pivotal PANOVA-3 trial
locally advanced pancreatic cancersource ↗
◆Interim AnalysisTrial
Interim analysis of phase 3 pivotal INNOVATE-3 trial
recurrent ovarian cancersource ↗
◆Timing GuidancePresentation
Multiple interim or final data readouts expected within next three years from three ongoing phase 3 pivotal trials
◆Interim AnalysisTrial
Interim analysis of phase 3 pivotal PANOVA-3 trial
locally advanced pancreatic cancersource ↗
▲Other Regulator MilestoneOptuneFiledEx-US Regulatory
Medicare final local coverage determination for Optune in newly diagnosed GBM
newly diagnosed glioblastomasource ↗
▲FDA ApprovalovoTTF-100LApprovedFDA Decision
FDA approval of NovoTTF-100L System for malignant pleural mesothelioma via Humanitarian Device Exemption
malignant pleural mesotheliomasource ↗
▲Other Regulator MilestoneOptuneFiledEx-US Regulatory
CMS establishes 2019 monthly fee schedule amount for Optune
newly diagnosed glioblastomasource ↗
Past FDA Catalysts and PDUFA Decisions
How NVCR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D37 / 100
Pipeline Score
$392M
Pipeline Value
Not rated
Valuation Signal
1
Drugs Scored
0.2x
rNPV / MCap
Top 49%
Micro Cap(rank 323 of 658)
Percentile Rank
NovoCure Limited faces pipeline headwinds (37/100), with $979M risk-adjusted pipeline value, led by Immune checkpoint inhibitors or docetaxel in Nonsmall Cell Lung Cancer (Phase 3).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Immune checkpoint inhibitors or docetaxel Small moleculeCompletedNCT02973789 | Nonsmall Cell Lung Cancer | Phase 3 | COMPLETED | 291 | Oct 9, 2024 |
Clinical Trial Results
Readouts, endpoints and source filings for every NVCR program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Tumor Treating Fields | gastric adenocarcinoma | Phase 2 | 2022-06-03 | confirmed objective response rate: 50%; duration of response: 10.3 months; one year survival: 72%; median progression free survival: 7.8 monthsRead More | Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer Confirmed objective rRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Puri Michal NathOfficer (Chief Human Resources Officer) | Grant/Award | 1,905 203,227 held | $11.15 | 06/30/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in NVCR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| SOLEUS CAPITAL MANAGEMENT, L.P. | 5.2 % (13 %) | 150.19 M | 9.91 M | -5.52% ( -578.99 K) |
NVCR Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How NVCR ranks across every disease it competes in
Competitive Position is a premium feature
See how NVCR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialNVCR News
NVCRNovocure’s Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer
Novocure has received approval from Japan's Ministry of Health for Optune Pax, a treatment for adult patients with unresectable locally advanced pancreatic cancer. This therapy will be used alongside gemcitabine and nab-paclitaxel. The approval is seen as a significant advancement in addressing the urgent need for effective treatments in this challenging disease area.
Read more →NVCRNovocure to Report Third Quarter 2026 Financial Results
Novocure is set to announce its financial results for the third quarter of 2026 on October 29, 2026. The report will be released before the U.S. markets open, followed by a conference call at 8:00 a.m. EDT to discuss the results. This event highlights the company's commitment to keeping stakeholders informed.
Read more →NVCRNovocure Announces Upcoming Investor Events
Novocure has announced its participation in two significant investor events. CEO Frank Leonard will engage in a fireside chat at the Wells Fargo Healthcare Conference on September 9, 2026, followed by one-on-one meetings. Additionally, he and CFO Christoph Brackmann will attend the Morgan Stanley Global Healthcare Conference on September 14, 2026.
Read more →NVCR▲ +28.4%on this news
Novocure Reports Second Quarter 2026 Financial Results
Novocure has announced its financial results for the second quarter of 2026, marking a significant achievement with record net revenues and an increase in active patients utilizing its Tumor Treating Fields therapy. CEO Frank Leonard highlighted this quarter as the company's strongest to date, reflecting positive growth in their oncology initiatives.
Read more →NVCRNovocure to Report Second Quarter 2026 Financial Results
Novocure is set to announce its financial results for the second quarter of 2026. The report will provide insights into the company's performance and financial health during this period. Investors and stakeholders are likely to pay close attention to the results for future projections.
Read more →NVCRNovocure’s Optune Pax® Receives CE Mark for the Treatment of Locally Advanced Pancreatic Cancer
Novocure's Optune Pax® has been granted CE Mark approval for treating locally advanced pancreatic cancer. This marks a significant advancement in therapeutic options for patients suffering from this challenging condition. The approval is expected to enhance treatment strategies and potentially improve patient outcomes.
Read more →NVCR▼ -20%on this news
Novocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma
Novocure has announced topline data from the Phase 3 TRIDENT trial, which evaluates the earlier use of Tumor Treating Fields therapy in patients with newly diagnosed glioblastoma. The results are expected to provide insights into the therapy's effectiveness in this patient population. Further details on the outcomes and implications of the trial have yet to be disclosed.
Read more →NVCR▲ +27.5%on this news· ran to +39% by day 1
Novocure Reports First Quarter 2026 Financial Results
Novocure reported strong financial results for Q1 2026, with net revenues of $174.1 million, a 12% increase from the previous year. The company achieved key milestones in its commercial and clinical programs, including positive results from the PANOVA-4 trial. However, it also reported a net loss of $71.1 million and a significant rise in general and administrative expenses.
Read more →NVCRNovocure to Report First Quarter 2026 Financial Results
Novocure is scheduled to report its financial results for Q1 2026 on April 30, 2026. A conference call will be held at 8:00 a.m. EDT to discuss these results. The company is known for its innovative cancer treatment, Tumor Treating Fields, and has ongoing clinical trials for various cancers. Novocure emphasizes transparency through its investor relations website.
Read more →NVCRNovocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer
Novocure has announced positive topline results from its Phase 2 PANOVA-4 clinical trial, which evaluated the efficacy of Tumor Treating Fields (TTFields) therapy for patients with metastatic pancreatic cancer. The results indicate that TTFields may offer a promising treatment option for this challenging condition. Further details on the trial's outcomes and implications are anticipated.
Read more →NVCRNovocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer
Novocure has received reimbursement approval for its Optune Lua device from Japan's Ministry of Health, Labour and Welfare. This device is intended for adult patients with unresectable advanced or recurrent non-small cell lung cancer (NSCLC) who have progressed after platinum-based chemotherapy. The approval allows for concurrent use with PD-1/PD-L1 inhibitors, providing a significant treatment option for patients in Japan.
Read more →NVCRNovocure to Participate in 2026 Leerink Global Healthcare Conference
Novocure will participate in the 2026 Leerink Global Healthcare Conference, with CEO Frank Leonard and CFO Christoph Brackmann scheduled for a fireside chat. The event will take place on March 10, 2026, and will include one-on-one meetings with investors. A live audio webcast of the presentation will be available on Novocure's Investor Relations page.
Read more →NVCR▼ -8.3%on this newsshared move
Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update
Novocure reported its financial results for Q4 and full year 2025, highlighting a record number of patients treated with its Tumor Treating Fields therapy. The company announced the FDA approval of Optune Pax for pancreatic cancer, marking a significant milestone. Novocure aims for continued growth with projected revenue contributions from its therapies in 2026.
Read more →NVCR▲ +6.9%on this news· ran to +37% by day 1shared move
Tumor Treating Fields (TTFields) Therapy to be Covered for Patients with Newly Diagnosed Glioblastoma Through British Columbia Cancer (BC Cancer)
Novocure announced that British Columbia will cover Tumor Treating Fields (TTFields) therapy for newly diagnosed glioblastoma patients. This coverage follows a recommendation from Canada's Drug Agency, marking a significant milestone in treatment accessibility. The therapy aims to provide patients with a new option that may extend their survival. Novocure is committed to expanding access across Canada.
Read more →NVCR▲ +19.3%on this news
U.S. FDA Approves Novocure’s Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer
The U.S. FDA has approved Novocure's Optune Pax for treating locally advanced pancreatic cancer, marking a significant advancement in nearly three decades. The Phase 3 PANOVA-3 trial demonstrated improved overall survival and pain management without adding systemic side effects. Optune Pax utilizes Tumor Treating Fields to disrupt cancer cell replication, providing a new treatment option for patients.
Read more →NVCRNovocure to Present at 44th Annual J.P. Morgan Healthcare Conference
Novocure announced its participation in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, scheduled for January 12-15, 2026. CEO Frank Leonard will present and answer questions on January 14. The company aims to extend survival in aggressive cancer forms through its Tumor Treating Fields therapy. A live audio webcast of the presentation will be available.
Read more →NVCR▼ -8.8%on this news
Novocure Appoints Company President Frank Leonard as Chief Executive Officer
Novocure has appointed Frank Leonard as its new CEO, effective immediately. Leonard, who previously served as President, has been with the company for over 15 years and played a key role in its growth and development. He succeeds Ashley Cordova, who has resigned. Leonard aims to lead Novocure in launching new products and completing clinical trials.
Read more →NVCRNovocure to Participate in 37th Annual Piper Sandler Healthcare Conference
Novocure will participate in the 37th Annual Piper Sandler Healthcare Conference on December 2, 2025. Executive Chairman William Doyle will engage in a fireside chat and hold one-on-one meetings with investors. A live audio webcast of the presentation will be available for 14 days post-event. Novocure focuses on innovative cancer therapies.
Read more →NVCRNovocure Appoints Christoph Brackmann as Chief Financial Officer ROOT, Switzerland - Novocure (NASDAQ NVCR) announced today that Christoph Brackmann has been appointed as the company's next Chief Financial Officer (CFO).
Novocure has appointed Christoph Brackmann as its next Chief Financial Officer, effective immediately as a Senior Financial Advisor, with a formal transition to CFO set for January 1, 2025. Brackmann previously held the position of Senior Vice President of Finance at Moderna, where he contributed significantly during the COVID-19 pandemic. His experience in financial leadership is expected to aid Novocure in expanding its product offerings and global footprint, particularly in oncology therapeutics.
Read more →NVCRNovocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer
Novocure announced that the FDA has accepted its PMA application for Tumor Treating Fields therapy in treating non-small cell lung cancer (NSCLC) after platinum-based therapy. The application is based on the LUNAR trial data, which demonstrated improved survival rates for patients receiving TTFields therapy. A regulatory decision is expected in the second half of 2024.
Read more →About NovoCure Limited
HeadquartersNO. 4 THE FORUM, ST. HELIER
BIOPHARMAWATCH ELITE PLUS
Trade the next NVCR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime